Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 6/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 6/20 | 0.51 |
| ▸ | LTA4H | P09960 | 6/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | BTK | Q06187 | 6/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24665471 | 0.89 | CYP4F2 (0.54) | CYP4F2CYP4A11LTA4HKCNH2BTK | |
| SCHEMBL30006051 | 0.89 | CYP4F2 (0.54) | CYP4F2CYP4A11LTA4HKCNH2BTK | |
| SCHEMBL29123495 | 0.82 | CYP4F2 (0.48) | CYP4F2CYP4A11BTKATR | |
| SCHEMBL30005860 | 0.82 | CYP4F2 (0.48) | CYP4F2CYP4A11BTKATR | |
| SCHEMBL29123471 | 0.79 | CYP4F2 (0.48) | CYP4F2CYP4A11IDH1ATR | |
| SCHEMBL30005364 | 0.79 | CYP4F2 (0.48) | CYP4F2CYP4A11IDH1ATR | |
| SCHEMBL30006336 | 0.76 | LTA4H (0.46) | CYP4F2CYP4A11LTA4HKCNH2 | |
| SCHEMBL24665369 | 0.75 | LTA4H (0.61) | CYP4F2CYP4A11LTA4HKCNH2ATR | |
| SCHEMBL27204689 | 0.75 | LTA4H (0.59) | CYP4F2CYP4A11LTA4HKCNH2 | |
| SCHEMBL27171431 | 0.75 | LTA4H (0.59) | CYP4F2CYP4A11LTA4HKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022219546-A1 | HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H | NOVARTIS AG (CH) | 2022-10-20 | — | — | WO | disclosed |